See more : Smart Wires Technology Ltd. (GOGRID-SDB.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Itamar Medical Ltd. (ITMR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Itamar Medical Ltd., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- China Power International Development Limited (CPWIF) Income Statement Analysis – Financial Results
- Sembcorp Marine Ltd (S51.SI) Income Statement Analysis – Financial Results
- Li Bao Ge Group Limited (1869.HK) Income Statement Analysis – Financial Results
- Polaris Renewable Energy Inc. (RAMPF) Income Statement Analysis – Financial Results
- DMG Blockchain Solutions Inc. (DMGGF) Income Statement Analysis – Financial Results
Itamar Medical Ltd. (ITMR)
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 41.03M | 31.26M | 24.19M | 20.70M | 18.44M | 16.81M | 16.39M | 13.34M | 13.43M |
| Cost of Revenue | 12.32M | 6.98M | 5.73M | 5.00M | 4.98M | 4.40M | 4.80M | 4.26M | 3.80M |
| Gross Profit | 28.71M | 24.27M | 18.46M | 15.70M | 13.46M | 12.41M | 11.59M | 9.08M | 9.62M |
| Gross Profit Ratio | 69.97% | 77.66% | 76.33% | 75.84% | 73.00% | 73.81% | 70.72% | 68.07% | 71.68% |
| Research & Development | 6.00M | 4.52M | 3.64M | 4.13M | 3.23M | 2.83M | 2.02M | 1.89M | 1.69M |
| General & Administrative | 8.50M | 6.35M | 5.25M | 5.28M | 5.36M | 4.30M | 4.63M | 4.88M | 2.55M |
| Selling & Marketing | 24.55M | 18.29M | 12.70M | 12.14M | 14.04M | 10.68M | 8.44M | 7.40M | 5.69M |
| SG&A | 33.05M | 24.65M | 17.95M | 17.42M | 19.40M | 14.98M | 13.07M | 12.28M | 8.23M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 849.00K | 52.00K | 113.00K | 117.00K | 217.00K |
| Operating Expenses | 39.06M | 29.17M | 21.58M | 21.55M | 23.47M | 17.87M | 15.20M | 14.29M | 10.14M |
| Cost & Expenses | 51.38M | 36.15M | 27.31M | 26.55M | 28.45M | 22.27M | 20.00M | 18.54M | 13.94M |
| Interest Income | 713.00K | 454.00K | 93.00K | 1.39M | 547.00K | 176.00K | -571.00K | 714.00K | 121.00K |
| Interest Expense | 562.00K | 284.00K | 794.00K | 4.43M | 4.61M | 4.19M | 2.51M | 4.83M | 2.12M |
| Depreciation & Amortization | 1.82M | 1.29M | 481.00K | 509.00K | 434.00K | 367.00K | 324.00K | 400.00K | 330.00K |
| EBITDA | -8.43M | -3.66M | -330.00K | -280.00K | -9.23M | 2.44M | -313.00K | -7.73M | 2.76M |
| EBITDA Ratio | -20.55% | -11.71% | -1.36% | -1.35% | -50.04% | 14.53% | -1.91% | -57.95% | 20.57% |
| Operating Income | -10.34M | -4.89M | -3.12M | -5.85M | -10.01M | -5.46M | -3.61M | -5.21M | -515.00K |
| Operating Income Ratio | -25.21% | -15.66% | -12.90% | -28.25% | -54.30% | -32.48% | -22.02% | -39.04% | -3.84% |
| Total Other Income/Expenses | -468.00K | -337.00K | 1.52M | 632.00K | -4.26M | 3.35M | 458.00K | -7.76M | 831.00K |
| Income Before Tax | -10.81M | -5.23M | -1.61M | -5.22M | -14.27M | -2.11M | -3.15M | -12.96M | 316.00K |
| Income Before Tax Ratio | -26.35% | -16.73% | -6.64% | -25.20% | -77.40% | -12.57% | -19.23% | -97.20% | 2.35% |
| Income Tax Expense | 127.00K | 37.00K | 124.00K | 85.00K | 131.00K | 135.00K | 124.00K | -44.00K | -201.00K |
| Net Income | -10.94M | -5.27M | -1.73M | -5.30M | -14.40M | -2.25M | -3.28M | -12.92M | 517.00K |
| Net Income Ratio | -26.66% | -16.85% | -7.15% | -25.61% | -78.11% | -13.37% | -19.99% | -96.87% | 3.85% |
| EPS | -0.79 | -0.46 | -0.17 | -0.60 | -1.65 | -0.35 | -0.56 | -2.82 | 0.03 |
| EPS Diluted | -0.79 | -0.46 | -0.17 | -0.52 | -1.65 | -0.29 | -0.46 | -2.82 | 0.03 |
| Weighted Avg Shares Out | 13.85M | 11.54M | 10.13M | 8.80M | 8.75M | 6.39M | 5.83M | 4.58M | 16.42M |
| Weighted Avg Shares Out (Dil) | 13.85M | 11.54M | 10.13M | 10.13M | 8.75M | 7.73M | 7.15M | 4.58M | 16.42M |
The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) AbbVie Inc (NYSE: ABBV ) Agile Therapeutics Inc (NASDAQ: ...
The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aptose Biosciences ...
Equities Research Analysts' Updated EPS Estimates for January, 21st (ADM, AHT, BA, BT.A, CPI, CTEC, DLG, DRW3, FAN, FERG)
Equities Research Analysts’ updated eps estimates for Tuesday, January 21st: Admiral Group (LON:ADM) had its hold rating reissued by analysts at Peel Hunt. Ashtead Group (LON:AHT) had its price target boosted by Liberum Capital from GBX 2,616 ($34.41) to GBX...
The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 13.) Arvinas Inc (NASDAQ: ARVN ) Baxter International ...
Source: https://incomestatements.info
Category: Stock Reports